USE OF HEALTH ECONOMIC / PHARMACOECONOMIC INFORMATION BY DECISION-MAKERS ISSUES

IP1: PHARMACOECONOMICS IN IRELAND, SCOTLAND AND WALES: A CELTIC PERSPECTIVE ON THE APPRAISAL OF PHARMACEUTICALS
Moderator: Mike F Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Panelist(s): Dyfrig Hughes, PhD, Senior Research Fellow, University of Wales, Bangor, UK; Keith Tolley, MPhil, Research Director, Mapi Values, Bollington, Cheshire, UK; Mairin Ryan, BSc, Pharm, PhD, Health Information & Quality Authority, Lecturer in Pharmacoeconomics, Trinity College Dublin, Dublin, Ireland

IP2: WHAT IS THE ROLE OF COST-EFFECTIVENESS DATA IN THERAPEUTIC INNOVATION AND INEQUALITIES OF HEALTH CARE?
Moderator: John Hutton, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Panelist(s): Uwe Siebert, PhD, MPH, MSc, Professor of Public Health, University for Health Sciences, Medical Informatics and Technology, Vienna, Austria; Mark JC Nuijten, MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands; Elly A. Stolk PhD, Senior Research Associate, Institute for Medical Technology Assessment, Erasmus Medical Center, Rotterdam, The Netherlands

CLINICAL OUTCOMES/TREATMENT GUIDELINES ISSUES

IP3: INSTITUTIONAL DEVELOPMENTS IN HEALTH TECHNOLOGY ASSESSMENT AT MICRO AND MACRO LEVELS – IS RAISING STANDARDS THROUGH COMMON METHODOLOGIES AN ISSUE?
Moderator: Finn Boerlum Kristensen, MD, PhD, Director, National Board of Health, Copenhagen, Denmark
Panelist(s): Cari Almazan, Catalan Agency for Health Technology Assessment and Research (CAHTA), Barcelona, Spain; Americo Cicchetti, PhD, Professor of Health Care Management, Catholic University of Sacred Heart, Rome, Italy; Harri Sintonen, PhD, Professor, Department of Public Health, University of Helsinki, Helsinki, Finland

HEALTH CARE REIMBURSEMENT / COVERAGE ISSUES

IP4: REIMBURSEMENT DECISION PROCESSES IN EUROPE – IS THERE A POSSIBILTY OF PARTIALLY HARMONIZED APPROACH?
Moderator: Fabian Waechter, MD, MSc, Medical Assessor, Project Manager, AGES PharmMed - the Austrian Medicines Agency, Wien, Austria
Panelist(s): Richard Bergström, Vice Director, LIF Sweden, Stockholm, Sweden

HEALTH POLICY ISSUES

IP5: VALUE-BASED PRICING: SOLUTION OR ILLUSION?
Moderator: Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK.
Panelist(s): Martin Buxton, BSc, Professor of Economics and Director, Health Economics Research Group, Brunel University, London,UK; William Comanor, PhD, Professor, Department of Health Services, UCLA School of Public Health, Los Angeles, CA, USA; John O'Donnell, PhD, Sr. Director Health Policy, External Medical Affairs, AstraZeneca Pharmaceuticals, Wilmington, DE, USA.

USE OF HEALTH ECONOMIC / PHARMACOECONOMIC INFORMATION BY DECISION-MAKERS ISSUES

IP6: THE HTA “REVOLUTION” IN EUROPE: THE FUTURE IS BRIGHT, THE FUTURE IS COST-EFFECTIVENESS?
Moderator: Keith Tolley, MPhil, Research Director, Mapi Values, Bollington, Cheshire, UK
Panelist(s): Carole Longson, PhD, Director, National Institute for Health and Clinical Excellence (NICE), London, UK; Michael Barry, PhD, MD, Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital & Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland; Hilda Bastian, Head of Department; Health Information, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

HEALTH POLICY ISSUES

IP7: THE GERMAN WAY IN DEFINING AND APPLYING COST-EFFECTIVENESS-ANALYSES – REFLECTIONS FROM INTERNATIONAL EXPERIENCE
Moderator: Johann M Von der Schulenburg, PhD, Professor of Health Economics, Leibniz University Hannover, Hannover, Germany
Panelist(s): Peter T Sawicki, MD, Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; John Hutton, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Ulf Persson, PhD, Program Director, The Swedish Institute for Health Economics, IHE, Lund, Sweden

IP8: DISPARITIES IN ACCESS TO CANCER CARE – THE KAROLINSKA REPORT
Moderator: Frans Rutten, PhD, Professor, Institute for Medical Technology Assessment (iMTA), Rotterdam, The Netherlands
Panelist(s): Nils Wilking, MD, PhD, Associate Professor, Karolinska Institute, Stockholm, Sweden; Bengt Jönsson, PhD, Professor, Stockholm School of Economics, Stockholm, Sweden; Mark JC Nuijten, MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands

PHARMACOECONOMIC / HEALTH ECONOMIC STUDY METHODOLOGY ISSUES

IP9: IMPLEMENTING "GOOD REGISTRY PRACTICE" - NEWLY DEFINED BEST PRACTICE RECOMMENDATIONS FOR THE DESIGN, USE, AND EVALUATION OF PATIENT REGISTRIES
Moderator: Richard Gliklich, MD, President, Outcome, Cambridge, MA, USA
Panelist(s): Kathryn Starzyk, MS, Associate Director of Scientific Affairs, Outcome, Cambridge, MA, USA; Sarah Garner, PhD, MRPharmS, Technical Adviser, National Institute for Health and Clinical Excellence (NICE), London, UK

MEDICAL DEVICE, DIAGNOSTICS AND BIOTECHNOLOGY ISSUES

IP10: ARE MEDICAL DEVICES MORE CHALLENGING TO EVALUATE THAN DRUGS?
Moderator: Mike F Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Panelist(s): Rosanna Tarricone, DrPH, Economic Affairs Director, EUCOMED, Brussels, Belgium; Adrian Griffin, MSc, BSc, Director of Health Outcomes, Johnson & Johnson, High Wycombe, Buckinghamshire, UK; Rod Taylor, PhD, MSc, Reader, PenTAG, Peninsular Medical School, Exeter, UK

CONDITIONAL REIMBURSEMENT BASED ON FUTURE RESEARCH

CLINICAL OUTCOMES STUDY METHODOLOGY

W15: MIXED TREATMENT COMPARISON: A PRACTICAL APPROACH
DISCUSSION LEADERS: Sibilia Quilici, MSc, Senior Analyst, i3 Innovus, Health Outcomes, Uxbridge, Middlesex, UK; Keith Abrams, PhD, Professor of Medical Statistics, University of Leicester, Centre for Biostatistics & Genetic Epidemiology, Leicester, UK.

COST STUDY METHODOLOGY

W16: PROGRAMME BUDGETING AND MARGINAL ANALYSIS – ITS PLACE IN HEALTH ECONOMICS
DISCUSSION LEADERS: Monique Martin, MSc, MBA, Vice-President UK Operations, i3 Innovus, Uxbridge, Middlesex, UK; Alistair McGuire, PhD, Chair in Health Economics, London School of Economics, Health and Social Care, London, UK.

HEALTH CARE POLICY AND FORMULARY DEVELOPMENT USING OUTCOMES RESEARCH

W17: THE COST-EFFECTIVENESS THRESHOLD: A HURDLE FOR INNOVATION?
DISCUSSION LEADERS: Mark JC Nuijten, MD, PhD, MBA, Consultant, Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, The Netherlands; Rogier M Klok, PharmD, PhD, Health Outcomes Officer, Wyeth

W18: TRANSLATING CLINICAL TRIAL DATA TO LOCAL ENVIRONMENTS: THE VALIDITY OF EXTRAPOLATING DATA FOR HTA SUBMISSIONS
DISCUSSION LEADERS: Phil McEwan, PhD, Director, Cardiff Research Consortium, Cardiff, South Glamorgan, UK; Phil James, BSc, Director, CHKS, Alcester, Warwickshire, UK; Peter Sharplin, MSocSc, Head of Pharmaceutical Development, Cardiff Research Consortium, Cardiff, South Glamorgan, UK;

PATIENT-REPORTED OUTCOMES STUDY METHODOLOGY (INCLUDING PREFERENCE-BASED & COMPLIANCE STUDIES)

W19: IS THERE A CONSENSUS ON BEST-PRACTICE METHODS FOR STATED-PREFERENCE STUDIES?
DISCUSSION LEADERS: Semra Ozdemir, MS, Research Economist, RTI International, Research Triangle Park, NC, USA; F. Reed Johnson, PhD, Senior Fellow and Principal Economist, RTI International, Research Triangle Park, NC, USA; A. Brett Hauber, PhD, Senior Economist and Head, RTI International, Research Triangle Park, NC, USA

CLINICAL OUTCOMES STUDY METHODOLOGY

W20: ASSESSING THE EFFECTIVENESS OF COUNTER MATCHING AS A TOOL FOR IMPROVING THE EFFICIENCY OF THE NESTED CASE CONTROL DESIGN IN EFFECTIVENESS STUDIES
DISCUSSION LEADERS: Victor A Kiri, MSc, PhD, Director of Pharmacoepidemiology, PAREXEL International, Peri Approval Clinical Excellence (PACE), Uxbridge, London, Middlesex, UK; Camille Maringe, MSc, Epidemiology Fellow, GlaxoSmithKline R&D, Worldwide Epidemiology, London, Middlesex, UK.

COST STUDY METHODOLOGY

W21: ANALYSIS OF SECOND ORDER UNCERTAINTY FOR PATIENT-LEVEL SIMULATION MODELS USING META-MODELS
DISCUSSION LEADERS: Jeremy VM Chancellor, MSc, Director, i3 Innovus, Health Economics and Outcomes, Uxbridge, Middlesex, UK; Patrick Mollon, MD, MBA, MSc, Senior Associate Director, Pfizer Ltd, Outcomes Research, Sandwich, Kent, UK; Samuel Aballéa, MSc, Lead Research Analyst, i3 Innovus, Health Economics and Outcomes, Uxbridge, Middlesex, UK.

W22: THE IMPACT OF DIFFERENT RESOURCE COST DEFINITIONS ON RESULTS, INTERPRETATIONS, AND COMPARABILITY OF HEALTH ECONOMIC STUDIES
DISCUSSION LEADERS: Sandra L. Tunis, PhD, Senior Research Scientist, IMS Health Consulting, Health Economics and Outcomes Research, Noblesville, IN, USA; Elise M. Pelletier, MS, Director, IMS Health Consulting, Health Economics and Outcomes Research, Watertown, MA, USA; Meaghan St. Charles, MS, Research Scientist, IMS Health Consulting, Health Economics and Outcomes Research, Noblesville, IN, USA; Phil McEwan, PhD, Director, Cardiff Research Consortium, Cardiff, South Glamorgan, UK.

HEALTH CARE POLICY AND FORMULARY DEVELOPMENT USING OUTCOMES RESEARCH

W23: OPPORTUNITIES AND BARRIERS FOR ASSESSMENT OF EMERGING HEALTH TECHNOLOGIES: THE CASE OF PHARMACOGENETICS
DISCUSSION LEADERS: Katherine Payne, PhD, Health Economist, Manchester University, Academic Unit of Medical Genetics, Manchester, UK; Hans-Peter Dauben, MD, Head, International Affairs, German Institute for Medical Documentation and Information, Cologne, Germany; Emma Gutierrez de Mesa, PhD, Scientific Officer, European Commission, DG-JRC, IPTS, Seville, Spain.

PATIENT-REPORTED OUTCOMES STUDY METHODOLOGY (INCLUDING PREFERENCE-BASED & COMPLIANCE STUDIES)

W24: INTRODUCTION TO PROBABILISTIC CHOICE MODELS FOR THE MEASUREMENT OF HEALTH STATES
DISCUSSION LEADERS: Paul Krabbe, PhD, Senior Researcher, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands